Cantor Fitzgerald initiated coverage of Camp4 Therapeutics (CAMP) with an Overweight rating and $7 price target Camp4 is developing ASOs targeting regulatory RNA, with its lead program CMP-SYNGAP-01 aiming to restore SynGAP protein expression in SYNGAP1 haploinsufficiency, with Phase 1 expected in 2H26, the analyst tells investors in a research note. The program resembles an early-stage Dravet-like story, supported by solid preclinical data and a derisked intrathecal ASO approach proven by Spinraza.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAMP:
- Camp4 Therapeutics initiated with an Overweight at Cantor Fitzgerald
- CAMP4 Initiates GLP Toxicology Studies for CMP-SYNGAP-01
- Camp4 Therapeutics initiates GLP toxicology studies for CMP-SYNGAP-01
- Promising Prospects for CAMP4 Therapeutics: Buy Rating Affirmed Amid Advancements in CMP-SYNGAP-01 Program and Strong Investor Confidence
- Apple initiated, Hershey upgraded: Wall Street’s top analyst calls